

116TH CONGRESS
1ST SESSION

S. _____

To require the Secretary of Health and Human Services to develop a standard set of evidence-based, clinical quality metrics for use under contractual agreements with pharmacies under Medicare part D.

IN THE SENATE OF THE UNITED STATES

Mr. CASSIDY introduced the following bill; which was read twice and referred to the Committee on _____

A BILL

To require the Secretary of Health and Human Services to develop a standard set of evidence-based, clinical quality metrics for use under contractual agreements with pharmacies under Medicare part D.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Transparency for
5 Pharmacists Act”.

1 **SEC. 2. REQUIRING THE SECRETARY TO DEVELOP A**
2 **STANDARD SET OF QUALITY METRICS FOR**
3 **USE UNDER CONTRACTUAL AGREEMENTS**
4 **WITH PHARMACIES UNDER MEDICARE PART**
5 **D.**

6 Section 1860D–4 of the Social Security Act (42
7 U.S.C. 1395w–104) is amended—

8 (1) by redesignating subsection (m) (relating to
9 program integrity transparency measures), as added
10 by section 6063(c) of the Substance Use-Disorder
11 Prevention that Promotes Opioid Recovery and
12 Treatment for Patients and Communities Act (Pub-
13 lic Law 115–271), as subsection (n); and

14 (2) by adding at the end the following new sub-
15 section:

16 “(o) DEVELOPMENT OF STANDARD SET OF QUALITY
17 METRICS FOR USE UNDER CONTRACTUAL AGREEMENTS
18 WITH PHARMACIES.—Not later than January 1, 2022,
19 the Secretary shall develop a standard set of evidence-
20 based, clinical quality metrics, in consultation with all rel-
21 evant stakeholders, including PDP sponsors of prescrip-
22 tion drug plans, Medicare Advantage organizations offer-
23 ing MA–PD plans, pharmacy benefit managers, chain and
24 independent pharmacies, applicable government agencies,
25 specialty pharmacy providers, long-term care pharmacies,
26 and pharmacist practitioner organizations, from which

1 PDP sponsors of prescription drug plans and Medicare
2 Advantage organizations offering MA–PD plans would be
3 required to base their contractual agreements with phar-
4 macies under this part with respect to covered part D
5 drugs.”.